Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials
Decramer, Marc × Anzueto, Antonio Kerwin, Edward Kaelin, Thomas Richard, Nathalie Crater, Glenn Tabberer, Maggie Harris, Stephanie Church, Alison #
The Lancet Respiratory Medicine vol:2 issue:6 pages:472-86
Combination long-acting bronchodilator treatment might be more effective than long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary disease (COPD). We aimed to compare the efficacy and safety of umeclidinium (UMEC) plus vilanterol (VI) with tiotropium (TIO) monotherapy, UMEC monotherapy, or VI monotherapy in patients with moderate to very severe COPD.